Evaluation of the national breast cancer screening program in Poland in 1999-2009.National Cancer Registry overview.
スポンサーリンク
概要
- 論文の詳細を見る
Background: The Polish breast cancer screening program was initiated as part of National Cancer Control Program in July 2005 by establishing a network of accredited regional centers and the central coordination point. The changes in reproduction behaviors and lifestyle in Poland have contributed to rapid increase of breast cancer incidence and mortality. The aim of this article is to describe the results of the program after 7 years from its implementation and to advocate for its continuance. <br/>Methods: Data on incidence and mortality due to breast cancer among women aged 50-69 were extracted from the National Cancer Registry. Annual reports of the National Cancer Control Program and other data provided by the Ministry of Health in Poland were analyzed. <br/>Results: Between January 1999 and December 2009 there were 142,307 new cases of breast cancer and 54,927 deaths because of it reported in Polish females. Poland is a country with relatively low and dynamically increasing incidence of breast cancer compared to Western European countries. The coverage of the nationwide screening program was around 40%.<br/>Conclusion: The late introduction of the screening program with a high recall rate resulted in dynamic increase of incidence. This leads to stabilization of the breast cancer mortality since more cases could be detected at early stage and treated more effectively. The Polish National Cancer Control Program which includes the breast cancer screening met the interim measures recommended in the European Guidelines and should be continued in the future with higher coverage on the target population.
著者
-
Sakamoto Junichi
Young Leaders Program in Healthcare Administration, Nagoya University Graduate School of Medicine
-
Harun-Or-Rashid Md.
Young Leaders' Program in Healthcare Administration, Nagoya University Graduate School of Medicine
-
Andrzej Piotrowski
Young Leaders' Program in Healthcare Administration, Nagoya University Graduate School of Medicine
-
Hirosawa Tomoya
Young Leaders' Program in Healthcare Administration, Nagoya University Graduate School of Medicine
-
Andrzej Piotrowski
Young Leaders' Program in Healthcare Administration, Nagoya University Graduate School of Medicine
-
Hirosawa Tomoya
Young Leaders' Program in Healthcare Administration, Nagoya University Graduate School of Medicine
-
Sakamoto Junichi
Young Leaders' Program in Healthcare Administration, Nagoya University Graduate School of Medicine
関連論文
- PROSPECTIVE STUDY ON THE EFFECT OF TOREMIFENE IN PATIENTS WITH ADJUVANT ANASTROZOLE FAILURE IN POSTMENOPAUSAL BREAST CANCER
- HIV/AIDS Related Knowledge and Risk Behaviors Among Female Sex Workers in Two Major Cities of Mongolia
- Risk Behaviours and Associated Factors among Medical Students and Community Youths in Myanmar
- KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING DENGUE AMONG PEOPLE IN PAKSE, LAOS
- From Translational Research to a Large Randomized Clinical Trial : A Long and Streanuous Way from Bench to Bedside
- Feasibility study of direct fentanyl patch introduction without prior opioid titration
- CANCERS AFFECTING WOMEN IN MALAYSIA
- Implementation and limitations of meta-analysis of randomized trials from the clinical biostatistician's point of view
- Evaluation of the national breast cancer screening program in Poland in 1999-2009.National Cancer Registry overview.
- A Phase III study of combination therapy of the oral fluorinated pyrimidine compound tegafur-uracil (UFT) with low dose cisplatin compared with UFT alone in patients with locally advanced gastric cancer as postoperative adjuvant chemotherapy
- Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin : report of a case
- Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan : ROOF study
- Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer : KMBOG0610B